Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies

References

• Botero JP, Lee K, Branchford BR, et al. Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica. 2020;105(4):888–894. doi:10.3324/haematol.2018.214239
   PubMed Web of Science ®Google Scholar
• Krause KA, Graham BC. Glanzmann Thrombasthenia. 2020. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. PMID: 30855858.
   Google Scholar
• Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011;118(23):5996–6005. doi:10.1182/blood-2011-07-365635
   PubMed Web of Science ®Google Scholar
• George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: the spectrum of clinical disease. Blood. 1990;75(7):1383–1395. doi:10.1182/blood.V75.7.1383.1383
   PubMed Web of Science ®Google Scholar
• Lee A, Poon MC. Inherited platelet functional disorders: general principles and practical aspects of management. Transfus Apher Sci. 2018;57(4):494–501. doi:10.1016/j.transci.2018.07.010
   Web of Science ®Google Scholar
• Borhany M, Fatima H, Naz A, Patel H, Shamsi T. Pattern of bleeding and response to therapy in Glanzmann thrombasthenia. Haemophilia. 2012;18(6):e423–5. doi:10.1111/hae.12017
   Web of Science ®Google Scholar
• Glanzmann E. Hereditare hämorrhagische thrombasthenie. Ein Beitrag zur Pathologie der Blutplättchen. Jb Kinderheilk. 1918;88:133. German.
   Google Scholar
• Bellucci S, Caen J. Molecular basis of Glanzmann’s thrombasthenia and current strategies in treatment. Blood Rev. 2002;16(3):193–202. doi:10.1016/s0268-960x(02)00030-9
   PubMed Web of Science ®Google Scholar
• Coller B. A brief history of ideas about platelets in health and disease. Platelets. 2007;170. doi:10.1016/B978-0-12-387837-3.00069-9
   Google Scholar
• Stevens RF, Meyer S. Fanconi and Glanzmann: the men and their works. Br J Haematol. 2002;119(4):901–904. doi:10.1046/j.1365-2141.2002.03812.x
   PubMed Web of Science ®Google Scholar
• Caen J, Cousin C. [“In vivo” disorder of platelet adhesiveness in Willebrand’s disease and Glanzmann’s thrombasthenias. Trial interpretation]. Nouv Rev Fr Hematol. 1962;2:685–694. [Slovenian].
   Google Scholar
• Phillips DR, Agin PP. Platelet membrane defects in Glanzmann’s thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest. 1977;60(3):535–545. doi:10.1172/JCI108805
   PubMed Web of Science ®Google Scholar
• Kunicki TJ, Aster RH. Deletion of the platelet-specific alloantigen PlA1 from platelets in Glanzmann’s thrombasthenia. J Clin Invest. 1978;61(5):1225–1231. doi:10.1172/JCI109038
   Web of Science ®Google Scholar
• Hagen I, Solum NO. Further studies on the protein composition and surface structure of normal platelets and platelets from patients with Glanzmann’s thrombasthenia and Bernard-Soulier syndrome. Thromb Res. 1978;13(5):845–855. doi:10.1016/0049-3848(78)90189-5
   Web of Science ®Google Scholar
• Nurden AT, Caen JP. The different glycoprotein abnormalities in thrombasthenic and Bernard-Soulier platelets. Semin Hematol. 1979;16(3):234–250.
   Web of Science ®Google Scholar
• Nurden AT. Inherited abnormalities of platelets. Thromb Haemost. 1999;82(2):468–480. doi:10.1055/s-0037-1615867
   Web of Science ®Google Scholar
• Coller BS, Cheresh DA, Asch E, Seligsohn U. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood. 1991;77(1):75–83. doi:10.1182/blood.V77.1.75.75
   PubMed Web of Science ®Google Scholar
• Nurden P, Poujol C, Nurden AT. The evolution of megakaryocytes to platelets. Baillieres Clin Haematol. 1997;10(1):1–27. doi:10.1016/s0950-3536(97)80048-0
   Web of Science ®Google Scholar
• Mitchell WB, Li J, French DL, Coller BS. alphaIIbbeta3 biogenesis is controlled by engagement of alphaIIb in the calnexin cycle via the N15-linked glycan. Blood. 2006;107(7):2713–2719. doi:10.1182/blood-2005-07-2990
   Web of Science ®Google Scholar
• Nurden AT, Pillois X, Fiore M, et al. Expanding the mutation spectrum affecting αIIbβ3 integrin in Glanzmann thrombasthenia: screening of the ITGA2B and ITGB3 genes in a large international cohort. Hum Mutat. 2015;36(5):548–561. doi:10.1002/humu.22776
   PubMed Web of Science ®Google Scholar
• Carrell NA, Fitzgerald LA, Steiner B, Erickson HP, Phillips DR. Structure of human platelet membrane glycoproteins IIb and IIIa as determined by electron microscopy. J Biol Chem. 1985;260(3):1743–1749. doi:10.1016/S0021-9258(18)89656-9
   Web of Science ®Google Scholar
• González-Manchón C, Fernández-Pinel M, Arias-Salgado EG, et al. Molecular genetic analysis of a compound heterozygote for the glycoprotein (GP) IIb gene associated with Glanzmann’s thrombasthenia: disruption of the 674–687 disulfide bridge in GPIIb prevents surface exposure of GPIIb-IIIa complexes. Blood. 1999;93(3):866–875. doi:10.1182/blood.V93.3.866
   Web of Science ®Google Scholar
• Yang J, Ma YQ, Page RC, Misra S, Plow EF, Qin J. Structure of an integrin alphaIIb beta3 transmembrane-cytoplasmic heterocomplex provides insight into integrin activation. Proc Natl Acad Sci U S A. 2009;106(42):17729–17734. doi:10.1073/pnas.0909589106
   PubMed Web of Science ®Google Scholar
• Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004;104(6):1606–1615. doi:10.1182/blood-2004-04-1257
   PubMed Web of Science ®Google Scholar
• Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood. 2008;112(8):3011–3025. doi:10.1182/blood-2008-06-077891
   PubMed Web of Science ®Google Scholar
• Armstrong PC, Peter K. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again. Thromb Haemost. 2012;107(5):808–814. doi:10.1160/TH11-10-0727
   Web of Science ®Google Scholar
• Zhu J, Negri A, Provasi D, Filizola M, Coller BS, Springer TA. Closed headpiece of integrin αIIbβ3 and its complex with an αIIbβ3-specific antagonist that does not induce opening. Blood. 2010;116(23):5050–5059. doi:10.1182/blood-2010-04-281154
   PubMed Web of Science ®Google Scholar
• Kieffer N, Phillips DR. Platelet membrane glycoproteins: functions in cellular interactions. Annu Rev Cell Biol. 1990;6:329–357. doi:10.1146/annurev.cb.06.110190.001553
   PubMedGoogle Scholar
• Farrell DH, Thiagarajan P. Binding of recombinant fibrinogen mutants to platelets. J Biol Chem. 1994;269(1):226–231. doi:10.1016/S0021-9258(17)42338-6
   Web of Science ®Google Scholar
• Du X, Ginsberg MH. Integrin αIIbβ3 and platelet function. Thromb Haemost. 1997;78(1):96–100. doi:10.1055/s-0038-1657508
   Web of Science ®Google Scholar
• Fiore M, d’Oiron R, Pillois X, Alessi MC. Anti-α. Br J Haematol. 2018;181(2):173–182. doi:10.1111/bjh.15087
   Web of Science ®Google Scholar
• Gemmell CH, Sefton MV, Yeo EL. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann’s thrombasthenia defect. J Biol Chem. 1993;268(20):14586–14589. doi:10.1016/S0021-9258(18)82371-7
   PubMed Web of Science ®Google Scholar
• Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”. J Clin Invest. 1996;98(3):863–874. doi:10.1172/JCI118859
   Web of Science ®Google Scholar
• Byzova TV, Plow EF. Networking in the hemostatic system. Integrin alphaiibbeta3 binds prothrombin and influences its activation. J Biol Chem. 1997;272(43):27183–27188. doi:10.1074/jbc.272.43.27183
   Web of Science ®Google Scholar
• Solh T, Botsford A, Solh M. Glanzmann’s thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. J Blood Med. 2015;6:219–227. doi:10.2147/JBM.S71319
   PubMed Web of Science ®Google Scholar
• Fiore M, Nurden AT, Nurden P, Seligsohn U. Clinical utility gene card for: Glanzmann thrombasthenia. Eur J Hum Genet. 2012;20(10). doi:10.1038/ejhg.2012.151
   Web of Science ®Google Scholar
• Ward CM, Kestin AS, Newman PJ. A Leu262Pro mutation in the integrin beta(3) subunit results in an alpha(IIb)-beta(3) complex that binds fibrin but not fibrinogen. Blood. 2000;96(1):161–169. doi:10.1182/blood.V96.1.161
   PubMed Web of Science ®Google Scholar
• Ruan J, Peyruchaud O, Alberio L, et al. Double heterozygosity of the GPIIb gene in a Swiss patient with Glanzmann’s thrombasthenia. Br J Haematol. 1998;102(4):918–925. doi:10.1046/j.1365-2141.1998.00852.x
   Web of Science ®Google Scholar
• French DL. The molecular genetics of Glanzmann’s thrombasthenia. Platelets. 1998;9(1):5–20. doi:10.1080/09537109876951
   PubMed Web of Science ®Google Scholar
• Schlegel N, Gayet O, Morel-Kopp MC, et al. The molecular genetic basis of Glanzmann’s thrombasthenia in a gypsy population in France: identification of a new mutation on the alpha IIb gene. Blood. 1995;86(3):977–982. doi:10.1182/blood.V86.3.977.977
   PubMed Web of Science ®Google Scholar
• Vinciguerra C, Bordet JC, Beaune G, Grenier C, Dechavanne M, Négrier C. Description of 10 new mutations in platelet glycoprotein IIb (alphaIIb) and glycoprotein IIIa (beta3) genes. Platelets. 2001;12(8):486–495. doi:10.1080/095371001317126383
   Web of Science ®Google Scholar
• Fullard J, Murphy R, O’Neill S, Moran N, Ottridge B, Fitzgerald DJ. A Val193Met mutation in GPIIIa results in a GPIIb/IIIa receptor with a constitutively high affinity for a small ligand. Br J Haematol. 2001;115(1):131–139. doi:10.1046/j.1365-2141.2001.03075.x
   Web of Science ®Google Scholar
• Tadokoro S, Tomiyama Y, Honda S, et al. Missense mutations in the β3 subunit have a different impact on the expression and function between αIIbβ3 and αvβ3. Blood. 2002;99(3):931–938. doi:10.1182/blood.v99.3.931
   Web of Science ®Google Scholar
• Loftus JC, O’Toole TE, Plow EF, Glass A, Frelinger AL, Ginsberg MH. A beta 3 integrin mutation abolishes ligand binding and alters divalent cation-dependent conformation. Science. 1990;249(4971):915–918. doi:10.1126/science.2392682
   PubMed Web of Science ®Google Scholar
• Bajt ML, Ginsberg MH, Frelinger AL, Berndt MC, Loftus JC. A spontaneous mutation of integrin alpha IIb beta 3 (platelet glycoprotein IIb-IIIa) helps define a ligand binding site. J Biol Chem. 1992;267(6):3789–3794. doi:10.1016/S0021-9258(19)50595-6
   Web of Science ®Google Scholar
• Chen YP, Djaffar I, Pidard D, et al. Ser-752–>Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proc Natl Acad Sci U S A. 1992;89(21):10169–10173. doi:10.1073/pnas.89.21.10169
   Web of Science ®Google Scholar
• Ganapule A, Jain P, Abubacker FN, et al. Surgical procedures in patients with Glanzmann’s thrombasthenia: case series and literature review. Blood Coagul Fibrinolysis. 2017;28(2):171–175. doi:10.1097/MBC.0000000000000524
   Web of Science ®Google Scholar
• Casati V, D’Angelo A, Barbato L, et al. Perioperative management of a heterozygous carrier of Glanzmann’s thrombasthenia submitted to coronary artery bypass grafting with cardiopulmonary bypass. Anesth Analg. 2006;103(2):309–311. doi:10.1213/01.ane.0000226087.11062.cd
   Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424. doi:10.1038/gim.2015.30
   PubMed Web of Science ®Google Scholar
• Nurden AT. Acquired antibodies to αIIbβ3 in Glanzmann thrombasthenia: from transfusion and pregnancy to bone marrow transplants and beyond. Transfus Med Rev. 2018;32(3):155–164. doi:10.1016/j.tmrv.2018.05.002
   Web of Science ®Google Scholar
• Kashiwagi H, Kunishima S, Kiyomizu K, et al. Demonstration of novel gain-of-function mutations of αIIbβ3: association with macrothrombocytopenia and glanzmann thrombasthenia-like phenotype. Mol Genet Genomic Med. 2013;1(2):77–86. doi:10.1002/mgg3.9
   PubMedGoogle Scholar
• Jayo A, Conde I, Lastres P, et al. L718P mutation in the membrane-proximal cytoplasmic tail of beta 3 promotes abnormal alpha IIb beta 3 clustering and lipid microdomain coalescence, and associates with a thrombasthenia-like phenotype. Haematologica. 2010;95(7):1158–1166. doi:10.3324/haematol.2009.018572
   Web of Science ®Google Scholar
• Gresele P, Falcinelli E, Giannini S, et al. Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families. Haematologica. 2009;94(5):663–669. doi:10.3324/haematol.2008.002246
   PubMed Web of Science ®Google Scholar
• Poncz M, Rifat S, Coller BS, et al. Glanzmann thrombasthenia secondary to a Gly273–>Asp mutation adjacent to the first calcium-binding domain of platelet glycoprotein IIb. J Clin Invest. 1994;93(1):172–179. doi:10.1172/JCI116942
   Web of Science ®Google Scholar
• Losonczy G, Rosenberg N, Boda Z, et al. Three novel mutations in the glycoprotein IIb gene in a patient with type II Glanzmann thrombasthenia. Haematologica. 2007;92(5):698–701. doi:10.3324/haematol.10847
   Web of Science ®Google Scholar
• Nurden P, Poujol C, Winckler J, Combrié R, Caen JP, Nurden AT. A Ser752–>Pro substitution in the cytoplasmic domain of beta3 in a Glanzmann thrombasthenia variant fails to prevent interactions between the alphaIIbbeta3 integrin and the platelet granule pool of fibrinogen. Br J Haematol. 2002;118(4):1143–1151. doi:10.1046/j.1365-2141.2002.03758.x
   Web of Science ®Google Scholar
• Sharma P, Kar R, Bhargava R, Ranjan R, Mishra PC, Saxena R. Acquired platelet dysfunction in 109 patients from a tertiary care referral hospital. Clin Appl Thromb Hemost. 2011;17(1):88–93. doi:10.1177/1076029610379397
   Web of Science ®Google Scholar
• Nurden AT. Acquired Glanzmann thrombasthenia: from antibodies to anti-platelet drugs. Blood Rev. 2019;36:10–22. doi:10.1016/j.blre.2019.03.004
   Web of Science ®Google Scholar
• Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511–6521. doi:10.1182/blood-2009-01-129155
   PubMed Web of Science ®Google Scholar
• Linge P, Fortin PR, Lood C, Bengtsson AA, Boilard E. The non-haemostatic role of platelets in systemic lupus erythematosus. Nat Rev Rheumatol. 2018;14(4):195–213. doi:10.1038/nrrheum.2018.38
   PubMed Web of Science ®Google Scholar
• Poon MC, Di Minno G, d’Oiron R, Zotz R. New insights into the treatment of Glanzmann thrombasthenia. Transfus Med Rev. 2016;30(2):92–99. doi:10.1016/j.tmrv.2016.01.001
   PubMed Web of Science ®Google Scholar
• Awidi AS. Increased incidence of Glanzmann’s thrombasthenia in Jordan as compared with Scandinavia. Scand J Haematol. 1983;30(3):218–222. doi:10.1111/j.1600-0609.1983.tb01477.x
   Google Scholar
• Iqbal I, Farhan S, Ahmed N. Glanzmann thrombasthenia: a clinicopathological profile. J Coll Physicians Surg Pak. 2016;26(8):647–650.
   Web of Science ®Google Scholar
• Franchini M, Favaloro EJ, Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta. 2010;411(1–2):1–6. doi:10.1016/j.cca.2009.10.016
   PubMed Web of Science ®Google Scholar
• Rosas RR, Kurth MH, Sidman J. Treatment and outcomes for epistaxis in children with Glanzmann’s thrombasthenia. Laryngoscope. 2010;120(12):2374–2377. doi:10.1002/lary.21034
   Web of Science ®Google Scholar
• Lowe GC, Lordkipanidzé M, Watson SP; group UGs. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders. J Thromb Haemost. 2013;11(9):1663–1668. doi:10.1111/jth.12332
   PubMed Web of Science ®Google Scholar
• Gresele P, Orsini S, Noris P, et al. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: a communication from the platelet physiology SSC. J Thromb Haemost. 2020;18(3):732–739. doi:10.1111/jth.14683
   PubMed Web of Science ®Google Scholar
• Rognoni E, Ruppert R, Fässler R. The kindlin family: functions, signaling properties and implications for human disease. J Cell Sci. 2016;129(1):17–27. doi:10.1242/jcs.161190
   PubMed Web of Science ®Google Scholar
• Lillicrap D, James P. Von Willebrand Disease: An Introduction for the Primary Care Physician. Montreal, QC, Canada: World Federation of Hemophilia; 2009.
   Google Scholar
• Michel M. Immune thrombocytopenic purpura: epidemiology and implications for patients. Eur J Haematol Suppl. 2009;71:3–7. doi:10.1111/j.1600-0609.2008.01206.x
   Google Scholar
• Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546. doi:10.7326/m19-1208
   PubMed Web of Science ®Google Scholar
• Gresele P, Harrison P, Bury L, et al. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. J Thromb Haemost. 2014;12(9):1562–1569. doi:10.1111/jth.12650
   PubMed Web of Science ®Google Scholar
• Kürekçi AE, Atay AA, Sarící SU, Zeybek C, Köseoğlu V, Ozcan O. Effect of iron therapy on the whole blood platelet aggregation in infants with iron deficiency anemia. Thromb Res. 2000;97(5):281–285. doi:10.1016/s0049-3848(99)00150-4
   Web of Science ®Google Scholar
• Akay OM, Akin E, Mutlu FS, Gulbas Z. Effect of iron therapy on platelet function among iron-deficient women with unexplained menorrhagia. Pathophysiol Haemost Thromb. 2008;36(2):80–83. doi:10.1159/000173726
   Google Scholar
• Moenen F, Vries MJA, Nelemans PJ, et al. Screening for platelet function disorders with multiplate and platelet function analyzer. Platelets. 2019;30(1):81–87. doi:10.1080/09537104.2017.1371290
   PubMed Web of Science ®Google Scholar
• McCabe White M, Jennings LK. Platelet Protocols: Research and Clinical Laboratory Procedures. Academic Press; 1999.
   Google Scholar
• Bolton-Maggs PH, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol. 2006;135(5):603–633. doi:10.1111/j.1365-2141.2006.06343.x
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost. 2008;34(8):709–733. doi:10.1055/s-0029-1145254
   PubMed Web of Science ®Google Scholar
• Mezzano D, Quiroga T, Pereira J. The level of laboratory testing required for diagnosis or exclusion of a platelet function disorder using platelet aggregation and secretion assays. Semin Thromb Hemost. 2009;35(2):242–254. doi:10.1055/s-0029-1220785
   Web of Science ®Google Scholar
• Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica. 2007;92(5):694–697. doi:10.3324/haematol.10999
   PubMed Web of Science ®Google Scholar
• Dacie SJV, Lewis SM. Practical Haematology. 6th ed. Churchill Livingstone; 1984.
   Google Scholar
• Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost. 2003;1(7):1628–1636. doi:10.1046/j.1538-7836.2003.00266.x
   PubMed Web of Science ®Google Scholar
• Philp R. Methods of Testing Proposed Anti Thrombotic Drugs. CRC Press; 1981.
   Google Scholar
• Mutreja D, Sharma RK, Purohit A, Aggarwal M, Saxena R. Evaluation of platelet surface glycoproteins in patients with Glanzmann thrombasthenia: association with bleeding symptoms. Indian J Med Res. 2017;145(5):629–634. doi:10.4103/ijmr.IJMR_718_14
   Web of Science ®Google Scholar
• Giannini S, Mezzasoma AM, Guglielmini G, Rossi R, Falcinelli E, Gresele P. A new case of acquired Glanzmann’s thrombasthenia: diagnostic value of flow cytometry. Cytometry B Clin Cytom. 2008;74(3):194–199. doi:10.1002/cyto.b.20396
   PubMed Web of Science ®Google Scholar
• Owaidah T, Saleh M, Baz B, et al. Molecular yield of targeted sequencing for Glanzmann thrombasthenia patients. NPJ Genom Med. 2019;4:4. doi:10.1038/s41525-019-0079-6
   Web of Science ®Google Scholar
• Bastida JM, Lozano ML, Benito R, et al. Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders. Haematologica. 2018;103(1):148–162. doi:10.3324/haematol.2017.171132
   PubMed Web of Science ®Google Scholar
• Downes K, Megy K, Duarte D, et al. Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. Blood. 2019;134(23):2082–2091. doi:10.1182/blood.2018891192
   PubMed Web of Science ®Google Scholar
• Simeoni I, Stephens JC, Hu F, et al. A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood. 2016;127(23):2791–2803. doi:10.1182/blood-2015-12-688267
   PubMed Web of Science ®Google Scholar
• Amesse C, Baillargeon L, Bissonnette D, et al. Glanzmann Thrombasthenia: An Inherited Bleeding Disorder. 2nd. Canadian Hemophilia Society & Canadian Association of Nurses in Hemophilia Care;2014.
   Google Scholar
• Mehta DN, Bhatia R. Dental considerations in the management of Glanzmann’s thrombasthenia. Int J Clin Pediatr Dent. 2010;3(1):51–56. doi:10.5005/jp-journals-10005-1054
   Google Scholar
• Almeida AM, Khair K, Hann I, Liesner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol. 2003;121(3):477–481. doi:10.1046/j.1365-2141.2003.04286.x
   PubMed Web of Science ®Google Scholar
• Jayakrishnan TT, Limonnik V, Shah D, Mewawalla P. Glanzmann’s thrombasthenia: how listening to the patient is sometimes the simple key to good medicine! Case Rep Med. 2020;2020:4862987. doi:10.1155/2020/4862987
   Web of Science ®Google Scholar
• Kulkarni B, Ghosh K, Shetty S. Second trimester prenatal diagnosis in Glanzmann’s thrombasthenia. Haemophilia. 2016;22(2):e99–e100. doi:10.1111/hae.12865
   Web of Science ®Google Scholar
• Soni P, Mantri S, Prabhudesai A, Patil R, Shanmukhaiah C, Shetty S. Triple jeopardy: a case of Glanzmann’s thrombasthenia with anti-GPIIb-IIIa antibodies and HPA incompatibility resulting in stillbirth. Thromb Res. 2019;181:141–144. doi:10.1016/j.thromres.2019.07.022
   Web of Science ®Google Scholar
• Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia. 2011;17(5):e858–69. doi:10.1111/j.1365-2516.2011.02516.x
   PubMed Web of Science ®Google Scholar
• Léticée N, Kaplan C, Lémery D. Pregnancy in mother with Glanzmann’s thrombasthenia and isoantibody against GPIIb-IIIa: is there a foetal risk? Eur J Obstet Gynecol Reprod Biol. 2005;121(2):139–142. doi:10.1016/j.ejogrb.2005.02.011
   Web of Science ®Google Scholar
• Forsyth AL, Zourikian N, Valentino LA, Rivard GE. The effect of cooling on coagulation and haemostasis: should “Ice” be part of treatment of acute haemarthrosis in haemophilia? Haemophilia. 2012;18(6):843–850. doi:10.1111/j.1365-2516.2012.02918.x
   Web of Science ®Google Scholar
• Forsyth AL, Zourikian N, Rivard GE, Valentino LA. An ‘ice age’ concept? The use of ice in the treatment of acute haemarthrosis in haemophilia. Haemophilia. 2013;19(6):e393–6. doi:10.1111/hae.12265
   Web of Science ®Google Scholar
• Levy JH, Koster A, Quinones QJ, Milling TJ, Key NS. Antifibrinolytic therapy and perioperative considerations. Anesthesiology. 2018;128(3):657–670. doi:10.1097/ALN.0000000000001997
   Web of Science ®Google Scholar
• Tengborn L, Blombäck M, Berntorp E. Tranexamic acid–an old drug still going strong and making a revival. Thromb Res. 2015;135(2):231–242. doi:10.1016/j.thromres.2014.11.012
   PubMed Web of Science ®Google Scholar
• Lombardo VT, Sottilotta G. Recombinant activated factor VII combined with desmopressin in preventing bleeding from dental extraction in a patient with Glanzmann’s thrombasthenia. Clin Appl Thromb Hemost. 2006;12(1):115–116. doi:10.1177/107602960601200120
   Web of Science ®Google Scholar
• Ghosh K, Kulkarni B, Shetty S, Nair S. Antiplatelet antibodies in cases of Glanzmann’s thrombasthenia with and without a history of multiple platelet transfusion. Indian J Hum Genet. 2009;15(1):23–27. doi:10.4103/0971-6866.50866
   Google Scholar
• Rajpurkar M, Chitlur M, Recht M, Cooper DL. Use of recombinant activated factor VII in patients with Glanzmann’s thrombasthenia: a review of the literature. Haemophilia. 2014;20(4):464–471. doi:10.1111/hae.12473
   PubMed Web of Science ®Google Scholar
• Poon MC, D’Oiron R, Von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann’s thrombasthenia: results of an international survey. J Thromb Haemost. 2004;2(7):1096–1103. doi:10.1111/j.1538-7836.2004.00767.x
   PubMed Web of Science ®Google Scholar
• Di Minno G, Zotz RB, d’Oiron R, et al. The international, prospective Glanzmann thrombasthenia registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica. 2015;100(8):1031–1037. doi:10.3324/haematol.2014.121475
   Web of Science ®Google Scholar
• Dubick MA, Dorfman R, Klemcke HG, et al. Stability of activated recombinant human factor VII (rFVIIa) after 28 days storage at 24° C and 43° C. Blood. 2008;112:4074. doi:10.1182/blood.V112.11.4074.4074
   Google Scholar
• Lak M, Scharling B, Blemings A, et al. Evaluation of rFVIIa (NovoSeven) in Glanzmann patients with thromboelastogram. Haemophilia. 2008;14(1):103–110. doi:10.1111/j.1365-2516.2007.01592.x
   PubMed Web of Science ®Google Scholar
• Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood. 2003;101(5):1864–1870. doi:10.1182/blood-2002-09-2761
   PubMed Web of Science ®Google Scholar
• Poon MC. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann’s thrombasthenia. Vasc Health Risk Manag. 2007;3(5):655–664.
   PubMedGoogle Scholar
• Birschmann I, Klamroth R, Eichler H, Schenk J, Kirchmaier CM, Halimeh S. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders. Haemophilia. 2013;19(5):679–685. doi:10.1111/hae.12156
   Web of Science ®Google Scholar
• Rakocz M, Lavie G, Martinowitz U. Glanzmann’s thrombasthenia: the use of autologous fibrin glue in tooth extractions. ASDC J Dent Child. 1995;62(2):129–131.
   Web of Science ®Google Scholar
• Franco R, Miranda M, Di Renzo L, De Lorenzo A, Barlattani A, Bollero P. Glanzmann’s thrombastenia: the role of tranexamic acid in oral surgery. Case Rep Dent. 2018;2018:9370212. doi:10.1155/2018/9370212
   Web of Science ®Google Scholar
• Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis. 2006;1:10. doi:10.1186/1750-1172-1-10
   PubMed Web of Science ®Google Scholar
• Herman MC, Mak N, Geomini PM, et al. Is the Pictorial Blood Loss Assessment Chart (PBAC) score associated with treatment outcome after endometrial ablation for heavy menstrual bleeding? A cohort study. BJOG. 2017;124(2):277–282. doi:10.1111/1471-0528.14434
   Web of Science ®Google Scholar
• Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol. 1990;97(8):734–739. doi:10.1111/j.1471-0528.1990.tb16249.x
   PubMedGoogle Scholar
• Nurden AT, Pillois X, Wilcox DA. Glanzmann thrombasthenia: state of the art and future directions. Semin Thromb Hemost. 2013;39(6):642–655. doi:10.1055/s-0033-1353393
   PubMed Web of Science ®Google Scholar
• Sherer DM, Lerner R. Glanzmann’s thrombasthenia in pregnancy: a case and review of the literature. Am J Perinatol. 1999;16(6):297–301. doi:10.1055/s-2007-993875
   Web of Science ®Google Scholar
• Boval B, Bellucci S, Boyer-Neumann C. Glanzmann’s thrombasthenia and pregnancy: clinical observations and management of four affected women Congress of the International Society of Thrombosis and Hemostasis. Thromb Haemost. 2001;P1154.
   Google Scholar
• Punt MC, Schuitema PCE, Bloemenkamp KWM, Kremer Hovinga ICL, van Galen KPM. Menstrual and obstetrical bleeding in women with inherited platelet receptor defects-A systematic review. Haemophilia. 2020;26(2):216–227. doi:10.1111/hae.13927
   Web of Science ®Google Scholar
• Orsini S, Noris P, Bury L, et al. Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica. 2017;102(7):1192–1203. doi:10.3324/haematol.2016.160754
   PubMed Web of Science ®Google Scholar
• Poon MC, d’Oiron R, Zotz RB, et al. The international, prospective Glanzmann thrombasthenia registry: treatment and outcomes in surgical intervention. Haematologica. 2015;100(8):1038–1044. doi:10.3324/haematol.2014.121384
   Web of Science ®Google Scholar
• Nordisk N, Inc. NovoSeven® RT, coagulation factor VIIa (Recombinant) [package insert]. Plainsboro, NJ; 2019.
   Google Scholar
• Santoro C, Rago A, Biondo F, et al. Prevalence of allo-immunization anti-HLA and anti-integrin αIIbβ3 in Glanzmann thromboasthenia patients. Haemophilia. 2010;16(5):805–812. doi:10.1111/j.1365-2516.2010.02230.x
   Web of Science ®Google Scholar
• Laurian Y, Tisseron-Maury B, Bibi Triki T, Kaplan C, Gaudelus J. Red blood cell transfusion in patients with type 1 Glanzmann’s thrombasthenia. J Thromb Haemost. 2005;3(10):2346–2347. doi:10.1111/j.1538-7836.2005.01579.x
   Web of Science ®Google Scholar
• Vivier M, Treisser A, Naett M, et al. [Glanzmann’s thrombasthenia and pregnancy. Contribution of plasma exchange before scheduled cesarean section]. J Gynecol Obstet Biol Reprod. 1989;18(4):507–513. [French].
   Google Scholar
• Winkelhorst D, Murphy MF, Greinacher A, et al. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. Blood. 2017;129(11):1538–1547. doi:10.1182/blood-2016-10-739656
   PubMed Web of Science ®Google Scholar
• Rayment R, Brunskill SJ, Soothill PW, Roberts DJ, Bussel JB, Murphy MF. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev. 2011;5:CD004226. doi:10.1002/14651858.CD004226.pub3
   Web of Science ®Google Scholar
• Poon MC. The Use of recombinant activated factor VII in patients with Glanzmann’s thrombasthenia. Thromb Haemost. 2021;121(3):332–340. doi:10.1055/s-0040-1718373
   Web of Science ®Google Scholar
• Browning L, Dogra S, Bourbonnais J The use of recombinant factor VIIa use in a patient with Glanzmann’s Thrombasthenia and diffuse alveolar hemorrhage. Poster Presentation at Congress of Society of Critical Care Medicine; 2010; USA.
   Google Scholar
• Wertz D, Boveroux P, Péters P, Lenelle J, Franssen C. Surgical resection of a sphenoid wing meningioma in a patient with Glanzmann thrombasthenia. Acta Anaesthesiol Belg. 2011;62(2):83–86.
   PubMedGoogle Scholar
• Phillips R, Richards M. Venous thrombosis in Glanzmann’s thrombasthenia. Haemophilia. 2007;13(6):758–759. doi:10.1111/j.1365-2516.2007.01555.x
   Web of Science ®Google Scholar
• Bellucci S, Damaj G, Boval B, et al. Bone marrow transplantation in severe Glanzmann’s thrombasthenia with antiplatelet alloimmunization. Bone Marrow Transplant. 2000;25(3):327–330. doi:10.1038/sj.bmt.1702139
   Web of Science ®Google Scholar
• Bellucci S, Devergie A, Gluckman E, et al. Complete correction of Glanzmann’s thrombasthenia by allogeneic bone-marrow transplantation. Br J Haematol. 1985;59(4):635–641. doi:10.1111/j.1365-2141.1985.tb07358.x
   Web of Science ®Google Scholar
• Flood VH, Johnson FL, Boshkov LK, et al. Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia. Pediatr Blood Cancer. 2005;45(7):971–975. doi:10.1002/pbc.20365
   Web of Science ®Google Scholar
• Ishaqi MK, El-Hayek M, Gassas A, et al. Allogeneic stem cell transplantation for Glanzmann thrombasthenia. Pediatr Blood Cancer. 2009;52(5):682–683. doi:10.1002/pbc.21888
   Web of Science ®Google Scholar
• Kitko CL, Levine JE, Matthews DC, Carpenter PA. Successful unrelated donor cord blood transplantation for Glanzmann’s thrombasthenia. Pediatr Transplant. 2011;15(3):e42–6. doi:10.1111/j.1399-3046.2009.01251.x
   Web of Science ®Google Scholar
• Wiegering V, Sauer K, Winkler B, Eyrich M, Schlegel PG. Indication for allogeneic stem cell transplantation in Glanzmann’s thrombasthenia. Hamostaseologie. 2013;33(4):305–312. doi:10.5482/HAMO-12-08-0014
   Web of Science ®Google Scholar
• Ramzi M, Dehghani M, Haghighat S, Nejad HH. Stem cell transplant in severe Glanzmann thrombasthenia in an adult patient. Exp Clin Transplant. 2016;14(6):688–690. doi:10.6002/ect.2014.0165
   Web of Science ®Google Scholar
• Fang J, Jensen ES, Boudreaux MK, et al. Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci U S A. 2011;108(23):9583–9588. doi:10.1073/pnas.1016394108
   Web of Science ®Google Scholar
• Sullivan SK, Mills JA, Koukouritaki SB, et al. High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood. 2014;123(5):753–757. doi:10.1182/blood-2013-10-530725
   PubMed Web of Science ®Google Scholar